Loading clinical trials...
Loading clinical trials...
Early Detection of Peripheral Neuropathy in Hereditary Transthyretin Amyloidosis
The purpose of the study is to evaluate and compare different tools that are used to detect evidence of peripheral neuropathy in patients with TTRv.
Early detection of peripheral neuropathy in patients with TTRv is important to support initiation of therapy that alters the course of the disease. Current tools used to detect peripheral neuropathy may not be sensitive, especially in very early and distal peripheral neuropathy. This study will compare different methods of assessing for peripheral neuropathy including using in-vivo reflectance confocal microscopy to assess for meissner corpuscles, serum neurofilament light chain, quantitative sensory testing, neuropathy impairement scores, nerve conduction studies and quality of life and symptoms questionnaires.
Age
30 - 90 years
Sex
ALL
Healthy Volunteers
Yes
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Start Date
February 14, 2022
Primary Completion Date
November 1, 2025
Completion Date
February 14, 2026
Last Updated
March 12, 2026
47
ACTUAL participants
neurofilament light chain
DIAGNOSTIC_TEST
In-vivo Meissner Corpuscle imaging
DIAGNOSTIC_TEST
Nerve conduction study
DIAGNOSTIC_TEST
Lead Sponsor
University of Pennsylvania
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions